Payment overview · 2025
General Payments
$395.93
16 reported records · 6 companies
Healthcare provider profile · identity verified
Rolando Perez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WESTON, FL · NPI 1457681165
Verified facts
What the public records show
CMS Open Payments records show Rolando Perez, M.D. received $395.93 in general payments during 2025 across 16 reported records.
Boston Scientific Corporation accounted for 46.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $183.44 | 46.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.75 | 14.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.88 | 13.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.31 | 13.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.49 | 8.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.06 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $395.93 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $109.21 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.75 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.88 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.88 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $53.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 176 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
176 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
91 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1266 | 378 |
| Atorvastatin Calcium | Atorvastatin Calcium | 949 | 281 |
| Amlodipine Besylate | Amlodipine Besylate | 919 | 269 |
| Levothyroxine Sodium | Levothyroxine Sodium | 554 | 149 |
| Lisinopril | Lisinopril | 515 | 141 |
| Losartan Potassium | Losartan Potassium | 421 | 128 |
| Omeprazole | Omeprazole | 395 | 132 |
| Hydrochlorothiazide | Hydrochlorothiazide | 364 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 95 |
| Metformin Hcl Er | Metformin Hcl | 332 | 99 |
| Metformin Hcl | Metformin Hcl | 311 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 85 |
| Valsartan | Valsartan | 261 | 73 |
| Trazodone Hcl | Trazodone Hcl | 234 | 72 |
| Carvedilol | Carvedilol | 217 | 66 |
| Alprazolam | Alprazolam | 207 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 198 | 76 |
| Alendronate Sodium | Alendronate Sodium | 186 | 64 |
| Simvastatin | Simvastatin | 178 | 53 |
| Mounjaro | Tirzepatide | 176 | 31 |
| Ezetimibe | Ezetimibe | 174 | 62 |
| Gabapentin | Gabapentin | 163 | 53 |
| Finasteride | Finasteride | 158 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 36 |
| Jardiance | Empagliflozin | 144 | 38 |
| Clonazepam | Clonazepam | 130 | 24 |
| Sertraline Hcl | Sertraline Hcl | 126 | 39 |
| Atenolol | Atenolol | 122 | 33 |
| Eliquis | Apixaban | 119 | 33 |
| Chlorthalidone | Chlorthalidone | 113 | 37 |
| Meloxicam | Meloxicam | 106 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 30 |
| Glimepiride | Glimepiride | 101 | 30 |
| Allopurinol | Allopurinol | 95 | 27 |
| Spironolactone | Spironolactone | 95 | 28 |
| Synthroid | Levothyroxine Sodium | 92 | 24 |
| Rybelsus | Semaglutide | 91 | 25 |
| Furosemide | Furosemide | 90 | 34 |
| Temazepam | Temazepam | 90 | 14 |
| Potassium Chloride | Potassium Chloride | 86 | 35 |
| Montelukast Sodium | Montelukast Sodium | 79 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 30 |
| Famotidine | Famotidine | 76 | 24 |
| Lorazepam | Lorazepam | 76 | 19 |
| Ozempic | Semaglutide | 74 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 69 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 17 |
| Pregabalin | Pregabalin | 62 | 14 |
| Azelastine Hcl | Azelastine Hcl | 60 | 33 |
| Buspirone Hcl | Buspirone Hcl | 60 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 11 |
| Januvia | Sitagliptin Phosphate | 57 | 18 |
| Hydrocortisone | Hydrocortisone | 56 | 29 |
| Mirtazapine | Mirtazapine | 56 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 20 |
| Ketoconazole | Ketoconazole | 55 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 15 |
| Eplerenone | Eplerenone | 50 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 11 |
| Ibuprofen | Ibuprofen | 49 | 18 |
| Prednisone | Prednisone | 49 | 32 |
| Nifedipine Er | Nifedipine | 48 | 15 |
| Torsemide | Torsemide | 48 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Irbesartan | Irbesartan | 46 | 12 |
| Bupropion Xl | Bupropion Hcl | 45 | 15 |
| Fenofibrate | Fenofibrate | 45 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 32 |
| Xarelto | Rivaroxaban | 44 | 13 |
| Ciclopirox | Ciclopirox | 43 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Donepezil Hcl | Donepezil Hcl | 41 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 18 |
| Valacyclovir | Valacyclovir Hcl | 38 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 11 |
| Benazepril Hcl | Benazepril Hcl | 32 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | 11 |
| Glipizide | Glipizide | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Naproxen | Naproxen | 28 | 12 |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Azithromycin | Azithromycin | 25 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395.93 · 16 records | Boston Scientific Corporation | Cologuard Collection Kit, EVENITY, MOUNJARO, NEXLETOL, Ozempic, PROLIA, Rybelsus, VersaCross Access Solution, WATCHMAN, WATCHMAN FLX, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error